Literature DB >> 28882961

Efficacy of N-acetylcysteine, D-mannose and Morinda citrifolia to Treat Recurrent Cystitis in Breast Cancer Survivals.

Debora Marchiori1, Pier Paolo Zanello2.   

Abstract

BACKGROUND/AIM: Breast cancer survivors in adjuvant therapy, frequently experience the estrogen deficiency with genitourinary symptoms mostly represented by recurrent bacterial cystitis. The objective of the present study was to evaluate the effectiveness of N-acetylcysteine, D-mannose and Morinda citrifolia fruit extract (NDM), when associated to antibiotic therapy, in reducing the persistence of recurrent cystitis in this risk population. PATIENTS AND METHODS: Sixty breast cancer survived women with recurrent cystitis were retrospectively examined. Group 1, comprised of 40 patients treated with antibiotic therapy associated with NDM lasting for six months, Group 2 comprised of 20 patients treated with antibiotics alone.
RESULTS: The use of NDM in combination with antibiotic therapy showed a significant reduction in positive urine cultures, compared to antibiotics alone. Subjects of Group 1 rather than those of Group 2, showed improvement in symptoms score of urgency, frequency, urge incontinence, recurrent cystitis, bladder and urethral pain.
CONCLUSION: In breast cancer survived women affected by genitourinary discomfort, the combination of NDM and antibiotic therapy showed a greater efficacy in reducing urinary tract infections and urinary discomfort with respect to antibiotic use only. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Breast cancer; D-mannose; N-acetylcysteine; cystitis; vaginal atrophy

Mesh:

Substances:

Year:  2017        PMID: 28882961      PMCID: PMC5656868          DOI: 10.21873/invivo.11149

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  11 in total

Review 1.  Persister cells.

Authors:  Kim Lewis
Journal:  Annu Rev Microbiol       Date:  2010       Impact factor: 15.500

2.  Prospective study to compare antibiosis versus the association of N-acetylcysteine, D-mannose and Morinda citrifolia fruit extract in preventing urinary tract infections in patients submitted to urodynamic investigation.

Authors:  Giovanni Palleschi; Antonio Carbone; Pier Paolo Zanello; Rita Mele; Antonino Leto; Andrea Fuschi; Yazan Al Salhi; Gennaro Velotti; Samer Al Rawashdah; Gianluca Coppola; Angela Maurizi; Serena Maruccia; Antonio L Pastore
Journal:  Arch Ital Urol Androl       Date:  2017-03-31

3.  Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society.

Authors:  D J Portman; M L S Gass
Journal:  Climacteric       Date:  2014-08-25       Impact factor: 3.005

4.  Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.

Authors:  Jason D Wright; Vrunda B Desai; Ling Chen; William M Burke; Ana I Tergas; June Y Hou; Melissa Accordino; Cande V Ananth; Alfred I Neugut; Dawn L Hershman
Journal:  Am J Obstet Gynecol       Date:  2017-03-21       Impact factor: 8.661

5.  An immunomodulatory polysaccharide-rich substance from the fruit juice of Morinda citrifolia (noni) with antitumour activity.

Authors:  A Hirazumi; E Furusawa
Journal:  Phytother Res       Date:  1999-08       Impact factor: 5.878

6.  Effects of human serum albumin, ibuprofen and N-acetyl-L-cysteine against biofilm formation by pathogenic Escherichia coli strains.

Authors:  P Naves; G del Prado; L Huelves; V Rodríguez-Cerrato; V Ruiz; M C Ponte; F Soriano
Journal:  J Hosp Infect       Date:  2010-07-07       Impact factor: 3.926

Review 7.  Genitourinary Syndrome of Menopause in Breast Cancer Survivors: Are We Facing New and Safe Hopes?

Authors:  Nicoletta Biglia; Valentina E Bounous; Luca G Sgro; Marta D'Alonzo; Silvia Pecchio; Rossella E Nappi
Journal:  Clin Breast Cancer       Date:  2015-06-18       Impact factor: 3.225

8.  Anti-inflammatory and potential cancer chemopreventive constituents of the fruits of Morinda citrifolia (Noni).

Authors:  Toshihiro Akihisa; Kazumi Matsumoto; Harukuni Tokuda; Ken Yasukawa; Ken-ichi Seino; Katsuo Nakamoto; Hideki Kuninaga; Takashi Suzuki; Yumiko Kimura
Journal:  J Nat Prod       Date:  2007-05-05       Impact factor: 4.050

9.  D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial.

Authors:  Bojana Kranjčec; Dino Papeš; Silvio Altarac
Journal:  World J Urol       Date:  2013-04-30       Impact factor: 4.226

10.  Effect of fosfomycin alone and in combination with N-acetylcysteine on E. coli biofilms.

Authors:  Anna Marchese; Micaela Bozzolasco; Laura Gualco; Eugenio A Debbia; Gian Carlo Schito; Anna Maria Schito
Journal:  Int J Antimicrob Agents       Date:  2003-10       Impact factor: 5.283

View more
  4 in total

1.  D-mannose vs other agents for recurrent urinary tract infection prevention in adult women: a systematic review and meta-analysis.

Authors:  Stacy M Lenger; Megan S Bradley; Debbie A Thomas; Marnie H Bertolet; Jerry L Lowder; Siobhan Sutcliffe
Journal:  Am J Obstet Gynecol       Date:  2020-06-01       Impact factor: 8.661

Review 2.  Systematic review of the effect of D-mannose with or without other drugs in the treatment of symptoms of urinary tract infections/cystitis (Review).

Authors:  Fabio Parazzini; Elena Ricci; Francesco Fedele; Francesca Chiaffarino; Giovanna Esposito; Sonia Cipriani
Journal:  Biomed Rep       Date:  2022-06-15

3.  Production, purification, characterization, and biological properties of Rhodosporidium paludigenum polysaccharide.

Authors:  Mengjian Liu; WenJu Zhang; Jun Yao; Junli Niu
Journal:  PLoS One       Date:  2021-01-29       Impact factor: 3.240

Review 4.  Role of D-mannose in urinary tract infections - a narrative review.

Authors:  Reeta Ala-Jaakkola; Arja Laitila; Arthur C Ouwehand; Liisa Lehtoranta
Journal:  Nutr J       Date:  2022-03-22       Impact factor: 3.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.